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Accurate seroprevalence estimates of SARS-CoV-2 in different populations could clarify the
extent to which current testing strategies are identifying all active infection, and hence the
true magnitude and spread of the infection. Our primary objective was to identify valid sero-
prevalence studies of SARS-CoV-2 infection and compare their estimates with the reported,
and imputed, COVID-19 case rates within the same population at the same time point.
Methods
We searched PubMed, Embase, the Cochrane COVID-19 trials, and Europe-PMC for pub-
lished studies and pre-prints that reported anti-SARS-CoV-2 IgG, IgM and/or IgA antibodies
for serosurveys of the general community from 1 Jan to 12 Aug 2020.
Results
Of the 2199 studies identified, 170 were assessed for full text and 17 studies representing
15 regions and 118,297 subjects were includable. The seroprevalence proportions in 8 stud-
ies ranged between 1%-10%, with 5 studies under 1%, and 4 over 10%—from the notably
hard-hit regions of Gangelt, Germany; Northwest Iran; Buenos Aires, Argentina; and Stock-
holm, Sweden. For seropositive cases who were not previously identified as COVID-19
cases, the majority had prior COVID-like symptoms. The estimated seroprevalences ranged
from 0.56–717 times greater than the number of reported cumulative cases–half of the stud-
ies reported greater than 10 times more SARS-CoV-2 infections than the cumulative num-
ber of cases.
Conclusions
The findings show SARS-CoV-2 seroprevalence is well below “herd immunity” in all coun-
tries studied. The estimated number of infections, however, were much greater than the
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number of reported cases and deaths in almost all locations. The majority of seropositive
people reported prior COVID-like symptoms, suggesting that undertesting of symptomatic
people may be causing a substantial under-ascertainment of SARS-CoV-2 infections.
Introduction
Globally, over one hundred and twenty million coronavirus disease (COVID-19) cases have
been reported to World Health Organization as of 15 March 2021 [1]. However, seropreva-
lence estimates based on immune response (serum antibodies) to SARS-CoV-2 rather than
reverse transcriptase polymerase chain reaction (RT-PCR) testing [2], may provide a more
accurate reflection of the true extent of SARS-CoV-2 infection among a population as many
people may have not been tested when they had active infection.
Valid seroprevalence estimates for a population rely on two major factors: (i) a representa-
tive population sample and (ii) accurate antibody testing. For example, testing should not be
biased by including predominantly symptomatic people or those exposed to a person with
COVID-19 [3]. Inappropriate sampling will bias the estimated seroprevalence, the infection
fatality rate, and the effective reproductive number (Rt) [4].
Systematic Reviews of the diagnostic accuracy SARS-CoV-2 antibodies have found con-
cerns about bias and applicability in the available studies. The sensitivity of most antibody-
tests, which measure immunoglobulin (Ig) M, IgG, and occasionally IgA antibodies against
SARS-CoV-2, appears to be low in the first week after onset of symptoms and increases up to
maximum value in the third week; data beyond three weeks are scarce [5–7]. Specificity of the
antibody tests has been estimated to exceed 98% for most tests; however, this may still result in
poor positive predictive values and high false positive rates in low prevalence settings [6].
Some evidence suggests that in infected asymptomatic people, a reduction of serum antibodies
is already observed during the early convalescent phase [8].
We aimed to identify all studies that reported seroprevalence estimates for SARS-CoV-2
infection using a representative sample of the target population, and to compare to these sero-
prevalence estimate with the cumulative incidence of confirmed COVID-19 cases, and
imputed case rates from the death rates, to establish the likely true extent of the infection
among a population.
Methods
We conducted a systematic review using enhanced processes with initial report completed
within two weeks, using daily short team meetings to review the progress, plan next actions,
and solve discrepancies and other obstacles [9]. We also used locally developed open access
automation tools and programs such as the Polyglot Search Translator, SearchRefiner, and the
SRA Helper to design, refine and convert our search strategy for all the databases we searched
and to speed up the screening process. We searched PubMed, Embase, Cochrane COVID-19
trials for published studies, and Europe PMC for pre-prints from 1 January to 12 August 2020.
A search string composed of Medical Subject Headings (MeSH) terms and words was devel-
oped in PubMed and was translated to be run in other databases [10] (see S1 File). We also
conducted forward and backward citation searches of the included studies in the Scopus
citation database. No restrictions on language were imposed. Review protocol was not
registered.
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Inclusion criteria
We included seroprevalence studies which attempted complete or random sample of the popu-
lation with more than 25% response rate to assess overall seroprevalence in general commu-
nity. We included seroprevalence testing that tested for anti-SARS-CoV-2 IgG, IgM, and IgA
antibodies in combination or separately.
We excluded studies with high risk of bias in sampling, i.e. the study sample was likely not
representative of the target population such as health care workers, blood donors, or dialysis
patients; government reports without sufficient details to evaluate risk of bias; modelling or
simulation studies even if they used real data (but sources of real data were checked for possi-
ble inclusion); lack of information about the antibody test(s) used to determine seropreva-
lence; and editorial or historical accounts without sufficient data to calculate the primary
outcome (e.g. insufficient details to allow identification of cumulative reported cases in the
population detected using RT-PCR). A list of excluded studies can be found in S1 Table with
reasons for exclusion.
Outcomes
Our primary outcomes were (1) the comparison of the seroprevalence based on antibody test-
ing in the study sample with the cumulative reported case incidence of people tested positive
for SARS-CoV-2 by RT-PCR in the same sample or in the target population cross-checked by
a cumulative incidence estimated from the cumulative COVID-19-specific mortality two
weeks after the seroprevalence and assuming a case-fatality rate of 1% [11]; and (2) frequency
of COVID-like symptoms among the study population prior to serological testing and odds of
testing positive with prominent COVID-related symptoms where data available.
Study selection and screening
Two authors (OB and CCD) independently screened titles, abstracts, and full texts according
to inclusion criteria. All discrepancies were resolved via group discussion with the other
authors. Reasons for exclusion were documented for all full text articles deemed ineligible
(S1 Table)—see PRISMA diagram (Fig 1).
Data extraction
Five authors (OB, CCD, KB, PG, DPR) extracted the following information from each study
and from related external sources:
• Participants: sampling frame, sample size, age, sex, setting, previous exposure or testing for
COVID-19
• Methods: study authors, country or region of the study, publication type, types of tests used,
date of seroprevalence sampling (to enable identification of separately reported cumulative
incidence rate in the sampling frame at around the same time as seroprevalence study).
• Outcomes: study seroprevalence (point estimate and confidence interval), adjusted seroprev-
alence (point estimate for the population adjusted for study design and test accuracy), and
cumulative COVID-19 cases in the study sample.
• Other information: when not provided in the study, we looked for publicly available data on
the cumulative incidence of COVID-19 and COVID-19 specific mortality in the study popu-
lation as close to the time of the study as possible.
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Risk of bias assessment
We used a combination of risk of bias tools for prevalence studies [12] and diagnostic accuracy
[13] and adapted the key signaling questions on sampling frame, ascertainment of immune
status, acceptability of methods and tests, and appropriateness of testing and sample collection
timeframe, as shown in S2 File in full.
Data synthesis
We used absolute numbers and proportions for the primary outcome. As only studies deemed
to be of sufficient quality after critical appraisal were included in the analysis, no sensitivity
analysis of high versus low quality studies was undertaken. We did not pool the estimates due
to heterogeneity of populations and study methods.
Fig 1. Screening and selection of articles for the review.
https://doi.org/10.1371/journal.pone.0248946.g001
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Results
We screened titles and abstracts of 2,199 articles and the full text of 170 articles for potential
inclusion (Fig 1). The major reason for exclusion was high risk of bias in the selection of partic-
ipants (Full list of excluded studies in S1 Table). Seventeen articles– 4 preprints, 11 published
studies, and 2 government reports–from 15 countries (Argentina, Brazil, Spain, Hungary, Ger-
many, Luxembourg, Switzerland, Denmark, Sweden, Finland, Iceland, the United States of
America (USA), the Channel Islands, Iran, and Japan) that tested a combined total of 118,297
participants met eligibility criteria [14–30]. (Table 1.)
Four studies provide national level data [16, 17, 20, 24], five studies report a province,
county or self-governing area level data [19, 22, 23, 26, 29], and the rest provide a city, town,
village or district level data. Seven studies tested participants over the age of 14 years [14, 17,
21, 24, 25, 28, 29] and ten tested population of all ages—the proportion of children and young
people (0–19 years) ranged from 7% to 26% and the proportion of participants aged over 60
years ranged from 7% to 37%. Eight studies tested for anti-SARS-CoV-2 IgG only or IgG and
IgA, the rest tested for IgG and IgM. (Table 1) Only five of the studies also collected nasopha-
ryngeal swabs for RT-PCR testing at the same time as serologic testing [15, 17, 22–24]. Infor-
mation on the serological test sensitivity and specificity is provided in S2 Table.
Seroprevalence
The seroprevalences ranged considerably (Table 2 and Fig 2): eight studies reported seropreva-
lence between 1%-10%; five studies had estimates under 1% [15, 17–19, 23] and four studies
had estimates over 10% [14, 21, 22, 26]. The unadjusted and adjusted seroprevalence estimates
in the included studies ranged from 0.22% in Rio Grande do Sul state in Brazil [23] to 53% in
the Barrio Mugica slum of Buenos Aires, Argentina [14].
The cumulative case incidence in the study population (based on RT-PCR testing) was
reported in five studies [15, 17, 22–24]. For the other studies we identified cumulative case
incidence data from publicly available online reports. For some studies the two types of esti-
mate were similar (e.g. Faroe island, Denmark), but for others the seroprevalence estimate
was substantially higher than the cumulative case estimate (e.g. in Guilan, Iran). Further details
on the study adjustment details and sources for cumulative incidence data are provided in
S2 Table.
The cumulative incidence rates at the regional levels (red squares and diamonds) ranged
from 0.006% in Utsunomiya, Tokyo [18] to 9.22% in Barrio Mugica slum of Buenos Aires,
Argentina [14]. The calculated cumulative case incidence for regions imputed from reported
COVID-19 deaths (assuming true CFR of 1%, brown crosses) ranged from 0.09% in Rio
Grande do Sul, Brazil [23] to 33.98% in Neustadt-am-Rennsteig, Germany [30]. The data col-
lection timeframes of the included studies are shown in S1 Fig in relation to the rolling 7-day
average of confirmed cases in each country.
The relationship between all the outcome estimates for each study/region on the log scale
are shown in Fig 2. The upper diagonal (identity) line indicates estimates that are equal to the
study seroprevalence estimate, and the lower diagonal line indicates estimates that are 1/10 or
1/100 that of the study seroprevalence estimate. In general, cases imputed from reported
deaths are next closest to the seroprevalence estimates, although there is considerable variation
in how close: imputed cases for Spain [20] matched the seroprevalence almost exactly, while
those for Guilan, Iran [22] were around 1/10 of the seroprevalence. Next closest were the study
cumulative case estimates, where differences in test accuracy of antibody vs RT-PCT tests may
explain most of the within study differences. The estimates that differed the most from those
of the study seroprevalence (furthest away from the identity line) were the reported regional
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Table 1. Characteristics of included studies (n = 17).
Study region, country,
author, publication status
Study population (sampling frame) Sample size, mean
age, sex, study dates
Type of serologic test and their Sensitivity and Specificity
Spanish national sero-
epidemiological survey
Pollán et al [20]
Published
Randomly selected population of Spain
from census data
n = 61,075
mean age 44 years
52% female
27 April—11 May
IgG and IgM: Orient Gene IgM/IgG, Zhejiang Orient Gene Biotech
Brazilian nationwide
survey
Hallal et al [16]
Preprint
Random samples of 133 large sentinel cities






IgG and IgM: WONDFO 459 SARS-CoV-2 Antibody Test (Wondfo
Biotech Co., Guangzhou, China)
Hungary
Merkely et al [17]
Published
Random sampling of representative
Hungarian population over 14 years of age.
n = 10,474
mean age 49 years
53.6% female
1–16 May
IgG: SARS-CoV2 IgG Reagent Kit, Abbott Laboratories, Irving, TX,
USA
Luxembourg
Snoeck et al [24]
Preprint
Random sample of Luxembourg population
over age of 18 (n = 514,921)
n = 1820
mean age 47 years
51% female
16 April—5 May
IgG and IgA: CE-labelled ELISA kits most recent versions from
Euroimmun.
Rio Grande do Sul, Brazil
Silviera et al [23]
Published
Random sample of population in Rio
Grande do Sul state (population 11.3mln)
n = 4500
mean age 48 years
59% female
9–11 May
IgG and IgM: WONDFO SARS-CoV-2 Antibody Test (Wondfo
Biotech Co., Guangzhou, China)
Faroe Island, Denmark
Petersen et al [19]
Published
Randomly selected population of the island
(population 52,154),
n = 1075
Mean age 42 years
50% female
27 April-1 May
IgG and IgM: SARS-CoV-2 Ab ELISA kit (Beijing Wantai Biologic
Pharmacy Enterprise)
LA county, USA
Sood et al [25]
Published
Random sample of LA county population n = 863
mean age 44 years
60% female
10–14 April
IgG and IgM: Lateral Flow Immunoassay test (Premier Biotech)
Jersey Island
The Channel Islands [29]
Report
Random sample of adult resident
population of Island of Jersey living in
private households
n = 855
mean age 48 years
53% female
29 April—5 May
IgG and IgM: Lateral Flow Immunoassay (Healgen COVID-19 IgG/
IgM)
Guilan, Iran
Shakiba et al [22]
Published
Random sample of population of Guilan
province, Iran (population 2,354,848)
n = 528
mean age 35 years
51% female
April
IgG and IgM: VivaDiag COVID-19 IgM/IgG from VivaChek
Reykjavik, Iceland
Gudbjartsson et al [15]
Published
Population of greater Reykjavik area who
had not been tested with PCR or had been
tested and negative
n = 4843
Mean age 48 years
38% female
27 April– 5 June
pan-Ig: IgM, IgG, & IgA against nucleoprotein (N) (Roche); the
receptor binding domain (Wantai); IgM & IgG against N (EDI/
Eagle); and IgG & IgA against the spike protein (Euroimmun).
Geneva, Switzerland
Stringhini et al [27]
Published
Random sample of Bus Santé study
participants, canton of Geneva
n = 1956
mean age 44 years
53% female
20 Apr-10 May
IgG: commercially available ELISA for IgG (Euroimmun AG,
Lübeck, Germany)
Stockholm, Sweden
Roxhed et al [21]
Preprint
Random household sample of adults (20–
74 years) in Stockholm
n = 1097
Mean age 47 years
55% female
April-May




Finnish Institute for Health
and Welfare Report [28]
Random sampling of adult population from





1 June– 6 Sep
IgG: against nucleoprotein and spike glycoprotein S1 and S2, the
antigens manufactured by The Native Antigen Company
Gangelt, Germany
Streeck et al [26]
Published
Random sample of population of Gangelt,
Germany (n = 12,597) from civil register
n = 919
mean age 53 years
51% female
31 Mar- 6 Apr
IgG and IgA: ELISA on the EUROIMMUN Analyzer I platform
(most recent CE version for IgG ELISA as of April 2020)
(Continued)
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case estimates, with several falling below the 1/100 seroprevalence line, some notably so (Gui-
lan, Iran) [22].
Ratio of seroprevalence to cumulative cases
Table 2 compares estimates of seroprevalence estimates to the cumulative reported cases. For
two studies—Rio Grande do Sul, Brazil, and the Faroe Islands, the seroprevalence was less




Study population (sampling frame) Sample size, mean
age, sex, study dates
Type of serologic test and their Sensitivity and Specificity
Barrio Mugica, Buenos
Aires, Argentina
Figar et al [14]
Preprint
Random sample of residents over 14 years
of age, Barrio Mugica slum (n = 40,000),
Buenos Aires city
n = 873
median age 38 years
57% female
10–26 June
IgG: COVIDAR IgG ELISA (Laboratorio Lemos SRL, Buenos Aires,
Argentina)
Utsunomiya, Japan
Nawa et al [18]
Published
Random selection of residents in
Utsunomiya City in Tochigi Prefecture,
Greater Tokyo, Japan
n = 742
Mean age 44 years
52.6% female
14 June-5 July
IgG: SARS-CoV2 IgG chemiluminescence assay from Shenzhen
YHLO Biotech Co., Ltd., Shenzhen, China
Neustadt-am-Rennsteig,
Germany
Weis et al [30]
Published
Whole population of Neustadt-am-
Rennsteig village, Germany (population
883)
N = 626
Mean age 60 years
53% female
12–22 May
IgG: two ELISA (Epitope Diagnostics Inc., San Diego, USA,
Euroimmun, Lübeck, Germany) and four chemiluminescence
assays (DiaSorin, Saluggia, Italy, Snibe Co., Ltd., Shenzhen, China,
Abbott, Chicago, USA, and Roche, Basel Switzerland)
https://doi.org/10.1371/journal.pone.0248946.t001
Table 2. Estimated cumulative incidence of infections based on seroprevalence estimates and comparison with the number of reported cases and imputed cases
from death rate.









Ratio of adjusted seroprevalence to
cases imputed from deaths
Rio Grande do Sul,
Brazil
0.22%/0.22% 0.396% 0.09% 0.56 2.53
Faroe island,
Denmark
0.56%/0.70% 0.79% NA 0.88 NA
Neustadt-am-
Rennsteig, Germany
8.39%/8.39% 5.55% 33.98% 1.51 0.25
Reykjavik, Iceland 0.90%/0.90% 0.50% 0.30% 1.80 3.00
Brazil 1.40%/1.00% 0.49% 1.90% 2.04 0.53
Luxembourg 1.92%/2.09% 0.62% 1.47% 3.37 1.42
Gangelt, Germany 13.60%/15.50% 3.10% 8.42% 5.00 1.84
Barrio Mugica,
Argentina
53.40%/53.40% 9.22% 13.75% 5.79 3.88
Geneva, Switzerland 8.28%/8.28% 1.01% 4.85% 8.23 1.71
Jersey Island 3.10%/3.10% 0.30% 1.53% 10.33 2.03
Stockholm, Sweden 10.48%/10.48% 0.85% 7.00% 12.33 1.50
Hungary 0.66%/0.68% 0.04% 0.45% 18.89 1.50
Southern Finland 3.03%/3.0% 0.14% 0.6% 20.78 4.96
LA county, USA 4.05%/4.65% 0.10% 0.36% 46.34 12.76
Spain 5.00%/5.00% 0.08% 5.00% 62.50 1.00
Utsunomiya City,
Japan
0.40%/1.23% 0.006% NA 193.30 NA
Guilan, Iran 22.16%/33.00% 0.05% 2.62% 717.39 12.60
https://doi.org/10.1371/journal.pone.0248946.t002
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10. The highest ratio was in Guilan, Iran, where the estimation of infections was 717 times
greater than the reported cases as of April 2020. Two studies did not report any COVID-19
related deaths among the participants so we could not impute case estimates for these studies
[17, 18]. For those studies we could impute the cumulative cases from deaths, the ratios were
generally much closer to 1, three being less than 1, and only two over 10.
Symptoms
Typical COVID-like symptoms prior to serologic testing [31] could help assess possible
untested or undetected cases. Nine of the 17 studies provided data on prior symptoms and mea-
sures varied (Table 3). Between 17% and 83% of the sero-positive participants in six studies
reported having typical COVID-like symptoms in the 2 weeks to 3 months prior to the serologic
testing. Prevalence of COVID-like symptoms were significantly more common among sero-
positive participants compared to the sero-negative participants. Positive serologic testing was
1.5 to 8.1 times more likely in people who had had any acute respiratory infection (ARI) symp-
toms; for the individual symptoms this ranged from 2-fold (fever) to 46-fold (loss of smell and
taste). Three studies also reported prevalence of other non-specific symptoms such as headache,
chest pain, skin rash, nausea, and fatigue among the participants [17, 24, 30].
Risk of bias of included studies
Table 4 summarizes the overall risk of bias assessment of the 17 included studies (see S2 File).
Most studies had low risk of bias for the sampling frame as they recruited participants ran-
domly from the general population (Domain 1). Majority of the studies reported response rate
over 50%. Five studies reported response rate in lower 30% or unclear (Domain 2). Domain 3
Fig 2. Log-log plot of study seroprevalence (x-axis) vs two cumulative case estimators for each study. Diagonal lines indicate rates equal
to seroprevalence (solid) or 1/10 seroprevalence (dashed).
https://doi.org/10.1371/journal.pone.0248946.g002
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assessed the potential to over- or underestimate the seroprevalence based on the diagnostic
accuracy of the individual antibody tests used in each study. Although each study provided
specificity and sensitivity for the tests based on internal or external (manufacturer) validation,
it was difficult to confidently evaluate the impact on the study results without a single-source
validation that would enable unbiased comparison. All studies but one used the same test and
type of test specimen in all study participants (Domain 4). The Spanish national serosurvey
did not venipuncture children and used only the rapid test (finger prick blood sample) and lab
test in adults. We evaluated the appropriateness of the timing of testing as low risk of bias as all
studies reported the dates of sample collection and testing as occurring after their local “pan-
demic wave” had passed. (Domain 5)
Discussion
The seroprevalence rates in eight studies ranged between 1%-10%, with 5 studies under 1%,
and 4 studies over 10%—notably hard-hit regions of Gangelt, Germany, Northwest Iran, the
Barrio Mugica slum of Buenos Aires, Argentina, and Stockholm, Sweden. For all but two stud-
ies, the seroprevalence estimate was higher than the cumulative reported case incidence, by a
factor between 1.5 to 717 times higher. However, the seroprevalence estimates were generally
much closer to the cumulative incidence imputed from deaths. Finally, we noted that many of
the seropositive cases had either typical or atypical symptoms.
The difference between seroprevalence and cumulative reported incidence might be
explained by three components: (i) asymptomatic cases (ii) atypical or pauci-symptomatic
cases, or (iii) the lack of access to, and uptake, of testing in different regions and countries. The
asymptomatic proportion found in studies of quarantine is around 17% [32], and so would
only explain a small proportion of the difference. The reports of symptoms suggest that atypi-
cal symptoms, such as anosmia, and as well as fever and cough were common in the seroposi-
tive but undetected cases. We further examined the difference between seroprevalence and
cumulative incidence by using a cumulative incidence imputed from the COVID-19 death
rates. A notable example is the study in North-West Iran where the apparent case fatality rate
is amongst the highest in the world, and there is also some evidence of under reporting of
COVID-19 deaths based on the comparison of excess deaths.
Table 3. Frequency of COVID-like or respiratory symptoms.
Study ID COVID-like symptoms among sero-
positives (%) (time period)
COVID-like symptoms among
sero-negatives (%)




Fever Cough Loss of smell
and taste
Spanish national survey (Pollán
et al [20])
52% (since 1 Feb) NA 8.1 NA NA NA
Hungary (Merkely et al [17]) 55% (previous 2 months) 42% 1.5 1.9 1.2 8
Luxembourg (Snoeck et al [24]) 54% (last 14 days) NA NA NA NA NA
LA county, USA (Sood et al [25]) 77% (previous 2 months) 25% NA 2.8 NA 4.1
Guilan, Iran (Shakiba et al [22]) 31% (previous 3 months) 22% 2.2 NA NA NA
Stockholm, Sweden (Roxhed et al
[21])
63%-83% (previous 2 months) 39% NA NA NA NA
Gangelt, Germany (Streeck et al
[26])
78% (since beginning of the pandemic on
15 Feb)
NA NA 4.9 2.8 18.5
Barrio Mugica, Argentina (Figar
et al [14])
17% (fever in the last 2 months) NA NA NA NA NA
Neustadt-am-Rennsteig, Germany
(Weis et al [30])
63% (last 2 months) 21% NA 5.8 4.8 46.5
https://doi.org/10.1371/journal.pone.0248946.t003
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Strengths of this review lie in the thorough search for published and unpublished literature,
strict inclusion criteria, and critical appraisal potential studies. However, there are several limi-
tations. First, while we excluded several studies because of their volunteer and/or responder
bias, several of the included studies still had significant degrees of non-response. Second, the
accuracy of the serological tests used was often unclear. A particular concern was the specificity
and possibility of false positive results in lower prevalence settings leading to potential overesti-
mation of seroprevalence [6]. For example, a specificity of 98% implies a 2% false positive rate
even in populations with few past infections. Third, to impute cumulative case incidence we
assumed a “true” case fatality rate of 1% for all populations [11] and did not allow for any lag-
time in using the mortality data. Finally, the inadequate reporting of many studies, particularly
the preprints, made the task of data extraction difficult. Many authors did not respond to data-
related questions emailed to the corresponding author.
There has been a couple of previous reviews of seroprevalence studies, but these focused on
using the studies to infer the infection fatality rate [33, 34]. We excluded some of the primary
studies they included because of the poor sampling methods, with high risk of bias from the
involvement of volunteers or low response rates. However, both reviews also demonstrated a
substantial variation in the seroprevalence rates but with an even greater range than our review
Table 4. Risk of bias in 14 included studies.
Risk of bias assessment questions
Included studies
1. Was the sampling
frame a true or close
representation of the
target population?
3. Is the diagnostic test
used likely to correctly
classify all past infections
in the target (at risk)
population?
3. Is the diagnostic test
used likely to correctly
classify all past infections
in the target (at risk)
population?











Rio Grande do Sul, Brazil
Faroe island, Denmark
LA county, USA










Green smiley face denotes low risk of bias; yellow straight face–moderate or unclear risk; and red sad face—high risk of bias.
https://doi.org/10.1371/journal.pone.0248946.t004
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because of the inclusion of studies with high risk of bias. The estimated under-ascertainment
of infections based on seroprevalence was 6 to 24 times the number of cumulative reported
cases in a study from the United States [35], most of the areas they investigated had an esti-
mated infection rates at least 10 times greater than the reported cases, which was similar to our
findings.
The results of this review have several implications for policy and practice. First, in all stud-
ies the estimated seroprevalences falls well short of that required for herd immunity suggesting
that herd immunity is unlikely to be achieved without mass vaccinations. Herd immunity
notion is often not based on robust data and policy makers need as much reliable data to make
better decisions as possible. Additionally, infection fatality rates are shown to increase several-
fold as the age of the people advance, further proving that herd immunity should not be pur-
sued through the natural course of a pandemic [36]. Reaching herd immunity does not
guarantee low or zero disease prevalence and susceptible individuals will still remain at risk
of infection [37]. Second, studies in regions with relatively thorough symptom-based testing
and detection show only a modest gap between the seroprevalence and the case cumulative
incidence, suggesting that much of the gap between reported cases and seroprevalence is
likely to be due to undetected symptomatic cases. Third, the short serial interval, days 3 to 5,
post-exposure enables the exposed person to become a source of transmission prior to devel-
oping symptoms [38]. Estimating cumulative cases on test-and-trace approaches that test
only symptomatic contacts will underestimates of community seroprevalence. Fourth, the
variation and incompleteness of methods used by the studies points to the need for better stan-
dardisation, design, and reporting of seroprevalence studies, including the need for better
questioning and reporting of subjects, prior history of RT-PCR testing, and history of
symptoms.
Routine testing for an immune response to COVID-19 in recovered patients allows not
only evaluation of the transmissibility of infection in general and specific populations, but
would provide improved estimations of attack rates and infection fatality rates, estimates
of possible immunity and evidence of reinfection [39–41]. The detection of antibodies estab-
lished from the studies we analysed does not infer herd immunity levels in their populations.
SARS-CoV-2 shares 79.6% sequence identity to SARS-CoV [42], and the peak level of IgG/
neutralising antibodies in recovered SARS-CoV patients occurred at 4–6 months before
declining [43]. Knowing the duration of immunity could inform strategic public health
approaches until a vaccine is available. Accurate estimates of immunity will not only require
repeat antibody testing among the population, but also establishing the association between a
positive antibody response and protective immunity against the disease. The current unknown
duration of IgG response and its association with disease immunity also raises questions about
the validity of an “immunity passport”, especially past a probable peak at 4–6 months post
infection [43, 44].
Findings of this review should help inform policy globally, but also trigger improved
research methods and better reporting of any future studies on seroprevalence. When there is
a large gap between seroprevalence estimates and incidence rates, strategies to extend case
finding and testing needs to be implemented. Evidence-based and targeted public health mea-
sures informed by accurate real-world data will help us successfully navigate the uncertain
dynamics of this new pandemic.
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